[1]
|
Huizinga, J.D., Thuneberg, L., Klüppel, M., et al. (1995) W/Kit Gene Required for Interstitial Cells of Cajal and for In-testinal Pacemaker Activity. Nature, 373, 347-349. https://doi.org/10.1038/373347a0
|
[2]
|
Verschoor, A.J., Bovée, J., Overbeek, L.I.H., et al. (2018) The Incidence, Mutational Status, Risk Classification and Referral Pattern of Gas-tro-Intestinal Stromal Tumours in the Netherlands: A Nationwide Pathology Registry (PALGA) Study. Virchows Archiv, 472, 221-229. https://doi.org/10.1007/s00428-017-2285-x
|
[3]
|
Søreide, K., Sandvik, O.M., Søreide, J.A., et al. (2016) Global Epidemiology of Gastrointestinal Stromal Tumours (GIST): A Systematic Review of Population-Based Cohort Studies. Cancer Epidemiology, 40, 39-46.
https://doi.org/10.1016/j.canep.2015.10.031
|
[4]
|
Fiore, M., Palassini, E., Fumagalli, E., et al. (2009) Preoperative Imatinib Mesylate for Unresectable or Locally Advanced Primary Gastrointestinal Stromal Tumors (GIST). European Journal of Surgical Oncology, 35, 739-745.
https://doi.org/10.1016/j.ejso.2008.11.005
|
[5]
|
Li, W., Li, X., Yu, K., et al. (2022) Efficacy and Safety of Neoad-juvant Imatinib Therapy for Patients with Locally Advanced Rectal Gastrointestinal Stromal Tumors: A Multi-Center Cohort Study. Frontiers in Pharmacology, 13, Article 950101. https://doi.org/10.3389/fphar.2022.950101
|
[6]
|
Yang, H., Shen, C., Yin, X., et al. (2021) Clinicopathological Fea-tures, Clinical Efficacy on 101 Cases of Rectal Gastrointestinal Stromal Tumors, and the Significance of Neoadjuvant Therapy. BMC Surgery, 21, Article No. 400.
https://doi.org/10.1186/s12893-021-01397-8
|
[7]
|
Sciot, R., Debiec-Rychter, M., Daugaard, S., et al. (2008) Dis-tribution and Prognostic Value of Histopathologic Data and Immunohistochemical Markers in Gastrointestinal Stromal Tumours (GISTs): An Analysis of the EORTC Phase III Trial of Treatment of Metastatic GISTs with Imatinib Mesylate. European Journal of Cancer, 44, 1855-1860.
https://doi.org/10.1016/j.ejca.2008.06.003
|
[8]
|
Bannon, A.E., Klug, L.R., Corless, C.L., et al. (2017) Using Mo-lecular Diagnostic Testing to Personalize the Treatment of Patients with Gastrointestinal Stromal Tumors. Expert Review of Molecular Diagnostics, 17, 445-457.
https://doi.org/10.1080/14737159.2017.1308826
|
[9]
|
Casali, P.G., Abecassis, N., Aro, H.T., et al. (2018) Gastro-intestinal Stromal Tumours: ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 29, Iv68-Iv78.
|
[10]
|
刘柏钶, 蔡兆伦, 张波. 晚期胃肠间质瘤新药相关I期临床试验进展[J]. 中国肿瘤临床, 2022, 49(2): 64-68.
|
[11]
|
Patel, S.R. and Reichardt, P. (2021) An Updated Review of the Treatment Landscape for Advanced Gastrointestinal Stromal Tumors. Cancer, 127, 2187-2195. https://doi.org/10.1002/cncr.33630
|
[12]
|
Boikos, S.A., Pappo, A.S., Killian, J.K., et al. (2016) Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report from the National Institutes of Health Gastroin-testinal Stromal Tumor Clinic. JAMA Oncology, 2, 922-928. https://doi.org/10.1001/jamaoncol.2016.0256
|
[13]
|
Cassier, P.A., Ducimetière, F., Lurkin, A., et al. (2010) A Pro-spective Epidemiological Study of New Incident GISTs during Two Consecutive Years in Rhône Alpes Region: Inci-dence and Molecular Distribution of GIST in a European Region. British Journal of Cancer, 103, 165-170. https://doi.org/10.1038/sj.bjc.6605743
|
[14]
|
Sun, Y., Yue, L., Xu, P., et al. (2022) An Overview of Agents and Treatments for PDGFRA-Mutated Gastrointestinal Stromal Tumors. Frontiers in Oncology, 12, Article 927587. https://doi.org/10.3389/fonc.2022.927587
|
[15]
|
Smrke, A., Gennatas, S., Huang, P., et al. (2020) Avapritinib in the Treatment of PDGFRA Exon 18 Mutated Gastrointestinal Stromal Tumors. Future Oncologyvol, 16, 1639-1646. https://doi.org/10.2217/fon-2020-0348
|
[16]
|
Joseph, C.P., Abaricia, S.N., Angelis, M.A., et al. (2021) Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncolo-gist, 26, E622-E631.
https://doi.org/10.1002/onco.13632
|
[17]
|
Jones, R.L., Serrano, C., Von, Mehren, M., et al. (2021) Avapritinib in Unresectable or Metastatic PDGFRA D842V-Mutant Gastrointestinal Stromal Tumours: Long-Term Efficacy and Safety Data from the NAVIGATOR Phase I Trial. European Journal of Cancer, 145, 132-142. https://doi.org/10.1016/j.ejca.2020.12.008
|
[18]
|
Corless, C.L., Barnett, C.M. and Heinrich, M.C. (2011) Gastroin-testinal Stromal Tumours: Origin and Molecular Oncology. Nature Reviews Cancer, 11, 865-878. https://doi.org/10.1038/nrc3143
|
[19]
|
Sihto, H., Sarlomo-Rikala, M., Tynninen, O., et al. (2005) KIT and Plate-let-Derived Growth Factor Receptor α Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors. Journal of Clinical Oncology, 23, 49-57. https://doi.org/10.1200/JCO.2005.02.093
|
[20]
|
Du, Z.Q., Dong, J., Li, M.X., et al. (2020) Overexpression of Platelet-Derived Growth Factor Receptor Α D842V Mutants Prevents Liver Re-generation and Chemically Induced Hepatocarcinogenesis via Inhibition of MET and EGFR. Journal of Cancer, 11, 4614-4624. https://doi.org/10.7150/jca.44492
|
[21]
|
Subramanian, S., West, R.B., Corless, C.L., et al. (2004) Gas-trointestinal Stromal Tumors (GISTs) with KIT and PDGFRA Mutations Have Distinct Gene Expression Profiles. On-cogene, 23, 7780-7790.
https://doi.org/10.1038/sj.onc.1208056
|
[22]
|
Kang, H.J., Koh, K.H., Yang, E., et al. (2006) Differentially Expressed Proteins in Gastrointestinal Stromal Tumors with KIT and PDGFRA Mutations. Proteomics, 6, 1151-1157. https://doi.org/10.1002/pmic.200500372
|
[23]
|
Lasota, J. and Miettinen, M. (2008) Clinical Significance of Onco-genic KIT and PDGFRA Mutations in Gastrointestinal Stromal Tumours. Histopathology, 53, 245-266. https://doi.org/10.1111/j.1365-2559.2008.02977.x
|
[24]
|
Szucs, Z., Thway, K., Fisher, C., et al. (2017) Molecular Subtypes of Gastrointestinal Stromal Tumors and Their Prognostic and Therapeutic Implications. Future Oncology, 13, 93-107. https://doi.org/10.2217/fon-2016-0192
|
[25]
|
Corless, C.L., Schroeder, A., Griffith, D., et al. (2005) PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and in Vitro Sensitivity to Imatinib. Journal of Clinical Oncology, 23, 5357-5364.
https://doi.org/10.1200/JCO.2005.14.068
|
[26]
|
Heinrich, M.C., Owzar, K., Corless, C.L., et al. (2008) Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Journal of Clinical Oncology, 26, 5360-5367. https://doi.org/10.1200/JCO.2008.17.4284
|
[27]
|
Farag, S., Somaiah, N., Choi, H., et al. (2017) Clinical Characteris-tics and Treatment Outcome in a Large Multicentre Observational Cohort of PDGFRA Exon 18 Mutated Gastrointestinal Stromal Tumour Patients. European Journal of Cancer, 76, 76-83. https://doi.org/10.1016/j.ejca.2017.02.007
|
[28]
|
Cassier, P.A., Fumagalli, E., Rutkowski, P., et al. (2012) Outcome of Patients with Platelet-Derived Growth Factor Receptor α-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. Clinical Cancer Research, 18, 4458-4464. https://doi.org/10.1158/1078-0432.CCR-11-3025
|
[29]
|
Mei, L., Smith, S.C., Faber, A.C., et al. (2018) Gastrointes-tinal Stromal Tumors: the GIST of Precision Medicine. Trends in Cancer, 4, 74-91. https://doi.org/10.1016/j.trecan.2017.11.006
|
[30]
|
中国临床肿瘤学会胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗共识(2017年版) [J]. 肿瘤综合治疗电子杂志, 2018, 4(1): 31-43.
|
[31]
|
Kang, W., Zhu, C., Yu, J., et al. (2015) KIT Gene Mutations in Gastrointestinal Stromal Tumor. Frontiers in Bioscience, 20, 919-926. https://doi.org/10.2741/4346
|
[32]
|
Iorio, N., Sawaya, R.A. and Friedenberg, F.K. (2014) Review Article: the Biol-ogy, Diagnosis and Management of Gastrointestinal Stromal Tumours. Alimentary Pharmacology & Therapeutics, 39, 1376-1386.
https://doi.org/10.1111/apt.12761
|
[33]
|
王媚媚, 秦晓红, 米立志. 血小板衍生生长因子受体结构与功能的研究[J]. 中国科学(生命科学), 2019, 49(6): 683-697.
|
[34]
|
Hemming, M.L., Heinrich, M.C., Bauer, S. and George, S. (2018) Translational Insights into Gastrointestinal Stromal Tumor and Current Clinical Advances. Annals of Oncology, 29, 2037-2045. https://doi.org/10.1093/annonc/mdy309
|
[35]
|
Appiah-Kubi, K., Lan, T., Wang, Y., et al. (2017) Platelet-Derived Growth Factor Receptors (PDGFRs) Fusion Genes Involvement in Hematological Malignancies. Criti-cal Reviews in Oncology/Hematology, 109, 20-34.
https://doi.org/10.1016/j.critrevonc.2016.11.008
|
[36]
|
Evans, E.K., Gardino, A.K., Kim, J.L., et al. (2017) A Preci-sion Therapy against Cancers Driven by KIT/PDGFRA Mutations. Science Translational Medicine, 9, eaao1690. https://doi.org/10.1126/scitranslmed.aao1690
|
[37]
|
Gebreyohannes, Y.K., Wozniak, A., Zhai, M.E., et al. (2019) Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors. Clinical Cancer Research, 25, 609-618. https://doi.org/10.1158/1078-0432.CCR-18-1858
|
[38]
|
Heinrich, M.C., Jones, R.L., Von Mehren, M., et al. (2020) Avapritinib in Advanced PDGFRA D842V-Mutant Gastrointestinal Stromal Tumour (NAVIGATOR): A Multicentre, Open-Label, Phase 1 Trial. The Lancet Oncology, 21, 935-946. https://doi.org/10.1016/S1470-2045(20)30269-2
|
[39]
|
Li, J., Zhang, X., Deng, Y., et al. (2023) Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multi-center Study. Oncologist, 28, 187-e114.
https://doi.org/10.1093/oncolo/oyac242
|
[40]
|
Kang, Y.K., George, S., Jones, R.L., et al. (2021) Avapritinib versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. Journal of Clinical Oncology, 39, 3128-3139. https://doi.org/10.1200/JCO.21.00217
|
[41]
|
许高奇, 张轶雯, 孔思思, 等. 酪氨酸激酶抑制剂的群体药动学研究进展[J]. 中国现代应用药学, 2020, 37(15): 1899-1906.
|
[42]
|
张轶雯, 潘宗富, 叶强, 等. 新一代TKI类药物瑞派替尼在胃肠间质瘤中的作用及研究进展[J]. 中国新药杂志, 2020, 29(23): 2690-2694.
|